Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,476
datasets available to search
ShareScore release 0.9.0
Dataset results
3,476 results for “Parkinson Disease”
Data from: Baseline C-reactive protein level and life prognosis in Parkinson disease
Background: C-reactive protein (CRP) is a biomarker of inflammation, and high levels of CRP correlate with vascular death. Chronic inflammation is considered to be involved in neurodegeneration, although there is no evidence linking it with the process of neurodegenerative diseases. Objective: To determine the role of baseline CRP levels in the prognosis of patients with Parkinson disease (PD). Methods: A cohort of 313 patients with a mean age of 69.1 and mean PD duration of 7.9 years was retrospectively followed for a mean observation time of 1,753 days. CRP was measured when patients were not diagnosed with any infections, and levels were repetitively measured to investigate a tendency of "regression to mean." The primary outcome measure was a survival time from study enrollment to death. Results: During the observation period 56 patients died. Baseline CRP was log-linearly associated with a risk of death in PD. Mean survival time was 3,149 (95% confidence interval; 3,009-3,289) days in patients with CRP ≤ 0.8mg/L (lower two thirds) and 2,620 (2,343-2,897) days in those with CRP > 0.8 mg/L (top third, p < 0.001, log-rank test). The adjusted hazard ratio (HR) per two-fold higher CRP concentration for all deaths was 1.29 (1.10-1.52), and after excluding PD-unrelated deaths, such as cancer or stroke, HR was 1.23 (1.01-1.49) (adjusted for age, sex, PD duration, modified Hohen-Yahr stages, MMSE scores, and serum albumin). Conclusions: Baseline CRP concentrations were associated with the risk of death and predicted life prognosis of patients with PD. The associations were independent from PD duration, PD severity, cognitive function, ages, and nutritional conditions, suggesting the possibility that subclinical chronic inflammation is associated with a neurodegenerative process in PD.
Data from: Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson's disease
Introduction A number of video-fluoroscopic swallowing study (VFSS) abnormalities have been reported in patients with Parkinson's disease (PD). However, the most crucial finding of subsequent aspiration pneumonia has not been validated fully. We conducted a retrospective and case-control study to determine the clinically significant VFSS findings in this population, and to propose a practical scale for predicting aspiration pneumonia in patients with PD. Methods We enrolled 184 PD patients who underwent VFSS because of suspected dysphagia. The patients who developed aspiration pneumonia within six months of the VFSS were assigned as cases and the patients without aspiration pneumonia at six months were designated as controls. Logistic regression analysis was performed to determine the prognostic VFSS features based on the data of swallowing 3 mL of jelly, which were used to make a PD VFSS scale (PDVFS). The validity of the new PDVFS was evaluated by ROC analysis. Additionally, we used the survival time analysis to compare time to death between groups, stratified by the PDVFS score. Results Twenty-five patients developed aspiration pneumonia. Among the previously-proposed VFSS features, mastication, lingual motility prior to transfer, aspiration, and total swallow time were identified as significant prognostic factors. We combined these factors to form the PDVFS. The PDVFS score ranges from 0 to 12, with 12 being the worst. ROC analysis revealed 92% sensitivity and 82% specificity at a cutoff point of 3. The higher PDVFS group showed shorter time-to-death than the lower PDVFS group (log rank P = 0.001). Conclusion Our newly developed VFSS severity scale (based on jelly swallowing) for patients with PD was easy to rate and could predict subsequent aspiration pneumonia and poor prognosis in patients with PD.
Box and Block Test and Nine-Hole Peg Test Variables in Patients with Parkinson's Disease.
Open the record for dataset details and reuse information.
Supplemental Data for "LRRK2 kinase activity regulates lysosomal glucocerebrosidase activity in neurons derived from Parkinson's disease patients"
<p>Sequencing of <em>GBA1</em> gene (all exons) and <em>LRRK2</em> (Exon 31 and 41) for all lines included in the manuscript: LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients. We do not observed unexpected point mutations in these genes in non-mutant cell lines. Primers for exon amplification and sequencing of GBA1 were obtained from Stone et al., 2000. PCR conditions were obtained from Lesage et al., 2011, Neumann et al., 2009, and Stone et al., 2000. </p>
Home-based online line bisection test detects visuo-spatial neglect and pseudoneglect in Parkinson's Disease
<p>Acquired data and analysis codes of the paper: </p> <p>Albert, Louis, et al. "Home-based online line bisection test detects visuo-spatial neglect and pseudoneglect in Parkinson's disease." <em>Parkinsonism & related disorders</em> 130 (2025): 107195.</p>
Data from: Framing advance care planning in Parkinson disease: patient and care partner perspectives
Objective: Advance care planning (ACP) is a core quality measure in caring for individuals with Parkinson's disease (PD) and there are no best practice standards for how to incorporate ACP into PD care. This study describes patient and care partner perspectives on ACP to inform a patient and care partner-centered framework for clinical care. Methods: Qualitative descriptive study of 30 patients and 30 care partners affected by PD within a multi-site, randomized clinical trial of neuropalliative care compared to standard care. Participants were individually interviewed about perspectives on ACP, including prior and current experiences, barriers to ACP, and suggestions for integration into care. Interviews were analyzed using theme analysis to identify key themes. Results: Four themes illustrate how patients and care partners perceive ACP as part of clinical care: 1) personal definitions of ACP vary in the context of PD; 2) patient, relationship, and healthcare system barriers exist to engaging in ACP; 3) care partners play an active role in ACP; 4) a palliative care approach positively influences ACP. Taken together, the themes support clinician initiation of ACP discussions and interdisciplinary approaches to help patients and care partners overcome barriers to ACP. Conclusions: ACP in PD may be influenced by patient and care partner perceptions and misperceptions, symptoms of PD (e.g. apathy, cognitive dysfunction, disease severity), and models of clinical care. Optimal engagement of PD patients and care partners in ACP should proactively address misperceptions of ACP and utilize clinic teams and workflow routines to incorporate ACP into regular care.
Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment
<p>Anxiety and depression in Parkinson’s disease (PD) reduce well-being of the patients. Emotional alterations influence motor skills and cognitive performance; moreover, they contribute significantly and independently to worsen rehabilitative treatment response. We investigated anxiety, depression, and quality of life in PD patients subjected to multidisciplinary rehabilitative training. The self-controlled study included 100 PD patients (49 males and 51 females with the mean age of 64.66 years) admitted to 60 days hospitalization rehabilitative program, between January 2017 and December 2018. Motor, cognitive, linguistic abilities, and functional independence were evaluated at admission (T0 baseline visit) and 60 days after (T1) the multidisciplinary rehabilitation including motor exercises, speech therapies, and cognitive intervention. The multidisciplinary rehabilitation improved functional status in PD patients and exerted its positive effects on mood, motor abilities, autonomy in the activities of daily life, perception of quality of life, cognitive performance and speech skills. Non-motor symptoms may worsen severe disability and reduce quality of life. They are often poorly recognized and inadequately treated. Nonetheless, multidisciplinary rehabilitative training represents an optimal strategy to improve disease management.</p>
Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem
<p>Background:Prevalence rates of sexual dysfunction (SD) in Parkinson's disease (PD) are likely to be under-estimated and their etiology is still unknown. More understanding of this issue is needed.Aim:To investigate prevalence of SD and its variables, including gender differences, in a sample of PD patients.Methods:This multicenter observational study included 203 patients (113 males and 90 females) affected byPD (diagnosed according to UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria 28), and livingin 3 different Italian regions. Patients were evaluated using a semi-structured interview (a 40-item ad hocquestionnaire, developed by the authors to investigate patient's 3 main life areas: sociodemographic information,illness perception, and sexuality) and specific standardized scales to investigate SD, as well as by means of tools toassess their motor impairment, daily life activities, and disease-related caregiver burden (CBI).Main Outcome Measures:The International Index of Erectile Function and the Female Sexual FunctionIndex.Results:Sexual dysfunction was observed in about 68% of men, and in around 53% of women loss of libidobeing the main sexual concern in both sexes. Men were significantly more affected by SD than women (c2(1)¼4.34,P-value¼.037), but no difference in the severity of the dysfunction emerged between genders.Around 85% of PD patients had a stable couple relationship, and about 40% were satisfied with such a rela-tionship. However, about 57% of the patients stated that the disease affected their sexual life, especially due toreduced sexual desire, and the frequency of sexual intercourses. Moreover, significant differences between subjectswith SD and subjects without SD were found in UPDRS (I-II-III domains), in Hamilton Depression RatingScale and CBI scores.Clinical Implications:Clinicians dealing with PD should pay more attention to sexual issues, as discussing andtreating sexual problems enters the framework of a holistic approach, which is mandatory in chronic illness.Strengths & Limitations:The major strengths of this study include the multicenter nature of the study, toovercome single-center methodological bias. The main limitation is the relatively small sample size, and theabsence of a control group, even if there are growing literature data on sexuality and aging supporting ourfindings.Conclusion:SD is a highly prevalent and devastating problem in patients affected by PD, negatively affectingtheir quality of life</p>
Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures--Cell Surface FCS
<p>FCS files corresponding to the cell surface experiment described in "Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures"</p> <p> </p>
Figure 1 from: Klein A (2016) Crowdsourcing voice editing and quality assessment of data collected from the largest mobile phone-based research study of Parkinson disease. Research Ideas and Outcomes 2: e8848. https://doi.org/10.3897/rio.2.e8848
Figure 1 - Amazon's Mechanical Turk Web site.
Figure 8 from: Klein A (2016) Crowdsourcing voice editing and quality assessment of data collected from the largest mobile phone-based research study of Parkinson disease. Research Ideas and Outcomes 2: e8848. https://doi.org/10.3897/rio.2.e8848
Figure 8 - Example artifacts in mPower voice recordings.
The effect of Computer Assisted Rehabilitation Environment (CAREN) in cognitive impairment and coping strategies in Parkinson's disease: a preliminary study
<p>Parkinson's disease is a neurodegenerative disorder characterized by different motor, vegetative, behavioral, and cognitive impairments, with worsening quality of life. Virtual reality devices have given promising results in neurorehabilitation as they can provide multisensory stimulation in a realistic environment. This study aims to test the efficacy of virtual reality training by using Computer Assisted Rehabilitation Environment in cognitive impairment in a sample of PD. 31 patients affected by PD were enrolled. All PD patients underwent 24 sessions of Computer Assisted Rehabilitation Environment training. The participants were assessed at baseline (T0) and after two months (T1). Our results suggested that Computer Assisted Rehabilitation Environment training may be effective in the cognitive and emotional domains, particularly by improving executive function, anxiety, and depressive symptoms. These changes have helped to improve self-efficacy and coping strategies. These results indicate greater cognitive and physical effort to overcome stressors. Our results show that Computer Assisted Rehabilitation Environment training was beneficial in improving cognitive functions. Longer duration training may be especially beneficial for patients with mild cognitive impairment. Our findings open the door to tailored personalized treatments based on the patient's motor and cognitive profiles.</p>
Summary stats for Andrews, Kukkle, Menon et al. Indian Parkinson's Disease GWAS
<p>GWAS summary stats for Andrews, Kukkle, Menon et al. "The genetic drivers of juvenile, young, and early-onset Parkinson's Disease in India"</p><p>Genomic coordinates in hg38. Results have been filtered for MAF > 0.05 and imputation quality (DR2) > 0.9. </p><p><i><strong>PDDiagnosis_GWAS.txt.gz</strong></i> - summary stats for PD diagnosis GWAS</p><p>CHR: chromosome</p><p>BP: base pair position</p><p>A1: effect allele</p><p>A2: alternative allele</p><p>BETA: odds ratio (with respect to A1)</p><p>SE: standard error</p><p>L95: confidence interval, lower bound</p><p>U95: confidence interval, upper bound</p><p>STAT: T-statistic</p><p>P: p-value</p><p>MAF: frequency of effect allele</p><p>MAF.cases: frequency of effect allele in cases (note: may exceed 0.5)</p><p>MAF.cont: frequency of effect allele in controls (note: may exceed 0.5)</p><p>DR2: Beagle imputation quality metric</p><p> </p><p><i><strong>AgeofOnset_GWAS.txt.gz</strong></i> - summary stats for age of onset GWAS</p><p>CHR: chromosome</p><p>BP: base pair position</p><p>A1: effect allele</p><p>A2: alternative allele</p><p>BETA: regression coefficient (with respect to A1)</p><p>SE: standard error</p><p>L95: confidence interval, lower bound</p><p>U95: confidence interval, upper bound</p><p>STAT: T-statistic</p><p>P: p-value</p><p>MAF: frequency of effect allele</p><p>DR2: Beagle imputation quality metric</p>
Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease
ClinicalTrials.gov study NCT00358189. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
ClinicalTrials.gov study NCT02278588. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pedunculopontine Nucleus Stimulation for Gait Disorders in Parkinson's Disease
ClinicalTrials.gov study NCT02055261. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
ClinicalTrials.gov study NCT06687837. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cognitive Therapy for Urinary Dysfunction in Parkinson´s Disease
ClinicalTrials.gov study NCT03917732. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Mapping Levodopa Effects on Cortico-basal Ganglia Circuit Function in Parkinson's Disease
ClinicalTrials.gov study NCT06240624. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Psychological Effects of Levodopa in Parkinson's Disease
ClinicalTrials.gov study NCT05119075. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.